Trial
NCT02418754
Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD)
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Regeneron Pharmaceuticals
Collaborators
—
Condition
Neovascular Age-Related Macular Degeneration
Intervention
REGN2176-3
Why stopped
No additional efficacy seen with REGN2176-3 over aflibercept alone
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-10-26